

## DAFTAR PUSTAKA

1. World Health Organiszation. [disitasi tanggal 10 Oktober 2022]. Tersedia dari: <http://www.who.int/cancer/en>. 2017.
2. Kementerian Kesehatan Republik Indonesia. Riset kesehatan dasar. Jakarta: Badan Penelitian dan Pengembangan Kesehatan Kementerian Kesehatan RI. 2013.
3. Ovarian Cancer (Cited on 10 October 2022) Available from: <http://www.cdc.gov/cancer/ovarian.index.htm>
4. Sihombing M, Sirait MA. Angka ketahanan hidup penderita kanker ovarium di RSUD. dr. Cipto Mangunkusumo Jakarta. *Majalah Kedokteran Indonesia*; 2007. volume 57.
5. World Health Organiszation. [disitasi tanggal 21 April 2020]. Tersedia dari [https://www.who.int/cancer/country-profiles/IDN\\_2020.pdf?ua=1](https://www.who.int/cancer/country-profiles/IDN_2020.pdf?ua=1)
6. INASGO. Indonesian Society of Gynecologic Oncology. Indonesia: INASGO. 2015-2019
7. Prawirohardjo S. *Onkologi Ginekologi*. Edisi Pertama. Jakarta: PT Bina Pustaka. 2010.
8. Nurlailiyani. Hubungan Antara Usia Pasien Dengan Derajat Keganasan Tumor Ovarium Primer Di RSUD DR. MOEWARDI Tahun 2011-2012. (2013).
9. Rasmussen CB, Kjaer SK, Albieri V, Bandera E V, Doherty JA, Høgdall E, et al. Pelvic Inflammatory Disease and the Risk of Ovarian Cancer and Borderline Ovarian Tumors: A Pooled Analysis of 13 Case-Control Studies. *Am J Epidemiol* [Internet]. 2017 [cited 2022 Oct 10];185(1):8–20. Available from: <http://www.ncbi.nlm.nih.gov/pubmed/27941069>
10. Tsilidis KK, Allen NE, Key TJ, Dossus L, Lukanova A, Bakken K, et al. Oral contraceptive use and reproductive factors and risk of ovarian cancer in the European Prospective Investigation into Cancer and Nutrition. *Br J Cancer* [Internet]. 2011 [cited2019 Apr 22];12:1436–42. Available from: [www.bjcancer.com](http://www.bjcancer.com)

11. Ferris JS, Daly MB, Buys SS, Genkinger JM, Liao Y, Terry MB. Oral contraceptive and reproductive risk factors for ovarian cancer within sisters in the breast cancer family registry. *British journal of cancer*; (2014). 110(4), 1074-1080.
12. Li K, Hüsing A, Fortner RT, Tjønneland A, Hansen L, et al. An epidemiologic risk prediction model for ovarian cancer in Europe: the EPIC study. *British journal of cancer*; (2015). 112(7), 1257-1265.
13. Tomao F, Lo Russo G, Spinelli GP, Stati V, Prete AA, Prinzi N, et al. Fertility drugs, reproductive strategies and ovarian cancer risk [Internet]. Vol. 7, *Journal of Ovarian Research*. 2014 [cited 2022 Oct 10]. Available from: <http://www.ovarianresearch.com/content/7/1/51>
14. Lo Russo G, Spinelli GP, Tomao S, Rossi B, Frati L, Panici PB, et al. Breast cancer risk after exposure to fertility drugs. *Expert Rev Anticancer Ther* [Internet]. 2013;13. Available from: <https://doi.org/10.1586/era.12.181>
15. Diergaard B, Kurta ML. Use of fertility drugs and risk of ovarian cancer [Internet]. Vol. 26, *Current Opinion in Obstetrics and Gynecology*. NIH Public Access; 2014 [cited 2019 Apr 22]. p. 125–9. Available from: <http://www.ncbi.nlm.nih.gov/pubmed/24752005>
16. Arania R, Windarti I. Karakteristik pasien kanker ovarium di rumah sakit Dr. H. Abdul Moeloek Bandar Lampung tahun 2009-2013. *Juke Unila*. 2015;5(9):43-7.
17. Ellis, Mahadevan. *Clinical anatomy: applied anatomy for students and junior doctors* [Internet]. 12th ed. Chichester: Wiley-Blackwell; 2010.
18. Moore KL, Dalley AF, Agur AMR, Moore ME. 2013. *Anatomi berorientasi klinis*. Edisike–5. Jakarta: Erlangga.
19. Eroschenko VP.. *Atlas histology difiore dengan korelasi fungsional*. Jakarta: EGC. 2010
20. George SHL, Garcia R, Slomovitz BM. Ovarian Cancer: The Fallopian Tube as the Site of Origin and Opportunities for Prevention. *Front Oncol* [Internet]. 2016 May 2 [cited 2019 Apr 22];6:108. Available from: <http://journal.frontiersin.org/Article/10.3389/fonc.2016.00108/abstract>

21. Doufekas K, Olaitan A. Clinical epidemiology of epithelial ovarian cancer in the UK [Internet]. Vol. 6, International Journal of Women's Health. Dove Press; 2014 [cited 2019 Apr 22]. p. 537–45. Available from: <http://www.ncbi.nlm.nih.gov/pubmed/24920935>
22. RJ Edmondson RJ, Monaghan JM. The epidemiology of ovarian cancer. *IntGynecolCancer*. 2001(11):423–9.
23. Kumolohadi RAR. Hubungan Antara Religiusitas Dengan Kecemasan Pada Penderita Kanker Ovarium Di Rumah Sakit Umum Daerah ARIFIN ACHMAD Pekanbaru. 2000 [cited 2019 Apr 17];000:740. Available from: [http://repository.uin-suska.ac.id/1189/1/2011\\_201136.pdf](http://repository.uin-suska.ac.id/1189/1/2011_201136.pdf)
24. Shafir AL, Rice MS, Gupta M, Terry KL, Rosner BA, Tamimi RM, et al. The Association Between Reproductive and Hormonal Factors and Ovarian Cancer by Estrogen- $\alpha$  and Progesterone Receptor Status. *Gynecol Oncol*. 2016;143(3):628-635
25. Moorman PG, Palmieri RT, Akushevich L, Berchuck A, Schildkraut JM. Ovarian cancer risk factors in african-american and white women. *Am J Epidemiol* [Internet]. 2009 Sep 1 [cited 2019 Apr 19];170(5):598–606. Available from: <http://www.ncbi.nlm.nih.gov/pubmed/19605513>
26. Hunn J, Rodriguez GC. Ovarian Cancer: Etiology, Risk Factors, and Epidemiology. *Clinical Obstetrics And Gynecology*. 2012;55:3–23.
27. Martini, F., & NATH, J. L. *Fundamentals of anatomy & physiology*. San Francisco, Pearson/Benjamin Cummings. (2009).
28. Diniz PM, Carvalho JP, Baracat EC, Carvalho FM. Fallopian tube origin of supposed ovarian high-grade serous carcinomas. *Clinics* [Internet]. 2011 [cited 2019 Apr 20];66(1):73–6. Available from: <http://www.ncbi.nlm.nih.gov/pubmed/21437439>
29. Johari AB, Siregar FG. Insidensi kanker ovarium berdasarkan faktor risiko di RSUP Haji Adam Malik tahun 2008-2011. *E-Jurnal FK USU*. 2013;1(1):1-6
30. Sung HK, Ma SH, Choi J-Y, Hwang Y, Ahn C, Kim B-G, et al. The Effect of Breastfeeding Duration and Parity on the Risk of Epithelial Ovarian

- Cancer: A Systematic Review and Meta-analysis. *J Prev Med Public Health* [Internet]. 2016 Nov [cited 2019 Apr 22];49(6):349–66. Available from: <http://www.ncbi.nlm.nih.gov/pubmed/27951628>
31. Wong AST, Auersperg N. Ovarian surface epithelium: family history and early events in ovarian cancer. *Reprod Biol Endocrinol*
  32. Sayasneh A, Tsivos D, Crawford R. Endometriosis and Ovarian Cancer: A Systematic Review. *ISRN Obstetrics and Gynecology*. 2011;2011:1-6.
  33. World Cancer Research Fund. Ovarian Cancer Report. *Contin Updat Proj* [Internet].2018;1–32.Availablefrom: <https://www.wcrf.org/sites/default/files/Ovarian-cancer-report.pdf>
  34. Robby. J. S, Mutter. L.G, Prat. J, Bentley. C. R, Russel.P, Anderson. C. M. Ovarian tumor. In: *Pathology of the female reproductive tract*.2th edition, Churchill livingstone; 2009.p.611-82
  35. GLOBOCAN. International Agency for Research on Cancer. Indonesia FactSheets[Internet].2018;1–32.Availablefrom: <https://gco.iarc.fr/today/data/factsheets/populations/360-indonesia-factsheets.pdf>
  36. Wang X, Li X, Su S, Liu M. Marital status and survival in epithelial ovarian cancer patients: A SEER-based study. *Oncotarget*. 2017;8(51):89040–54.
  37. Trudel-Fitzgerald C, Poole EM, Sood AK, Okereke OI, Kawachi I, Kubzansky LD, et al. Social Integration, Marital Status, and Ovarian Cancer Risk: A 20-Year Prospective Cohort Study. *Psychosom Med*. 2019;81(9):833–40.
  38. Kurman RJ, Ie-Ming S. The origin and pathogenesis of epithelial ovarian cancer: a proposed unifying theory. *Am J Surg Pathol*. 2010; 34(3):433-43.
  39. Simamora RPA, Hanriko R, Sari RDP. Hubungan usia , jumlah paritas , dan usia menarche terhadap derajat histopatologi kanker ovarium di RSUD Dr . H . Abdul Moeloek Bandar Lampung tahun 2015-2016. *Majority*. 2018;7(2):7–13.

40. Resti Arania I W. Karakteristik Pasien Kanker Ovarium di Rumah Sakit Dr. H. Abdul Moeloek Bandar Lampung Tahun 2009-2013. 2018;25(1):212–20.
41. Ardhiansyah AO. Dasar-dasar Onkologi. Airlangga University Press. Surabaya. 2017.p.37
42. Dheanisa Nofia, Syamel Muhammad IK, Abstrak. Analisis Faktor yang Berhubungan dengan Kejadian Kanker Ovarium Tipe Epitel di RSUP Dr. M. Djamil Padang Tahun 2017 - 2018 Dheanisa. J Ilm Ilmu Kesehat Wawasan Kesehat. 2019;6(1):20.
43. Loho MF, Wagey FW. Gambaran jenis kanker ovarium di RSUP Prof. Dr. R.D. Kandou Manado periode Januari 2013 - Desember 2015. 2016;4:2–6.
44. Fachlevy AF, Abdullah Z, Russeng SS. Faktor Risiko Kanker Ovarium di RSUP Wahidin Sudirohusodo Makassar. Fakultas Kesehatan Masyarakat. Universitas Hasanuddin. 2015.p.1-14
45. Gambaran Faktor-Faktor Risiko Penderita Kanker Ovarium di Rsud. Labuang Baji Makassar tahun 2013 kti [Internet]. [cited 2019 Apr 16]. Available from: <http://repositori.uinalauddin.ac.id/6866/1/Lisnawatiopt.pdf>
46. Dhitayoni IA, Budiana ING. Profil Pasien Kanker Ovarium Di Rumah Sakit Umum Pusat Sanglah Denpasar – Bali Periode Juli 2013 – Juni 2014. 2017;17(3):23–32.
47. Iversen L, Fielding S, Lidegaard Ø, Mørch LS, Skovlund CW, Hannaford PC. Association between contemporary hormonal contraception and ovarian cancer in women of reproductive age in Denmark: Prospective, nationwide cohort study. *BMJ*. 2018;362:1–9.
48. Ari Madi Yanti D, Sulistianingsih A. Faktor determinan terjadinya kanker ovarium di Rumah Sakit Umum Daerah Abdoel Moelok Provinsi Lampung 2015 Determinant Factors of Ovarium Cancer in Abdoel Moelok Hospital Lampung in 2015. 2016;7(2):79
49. Zheng G, Yu H, Kanerva A, Forsti A, Sundquist K, Hemminki K. Familial risks of ovarian cancer by age at diagnosis, proband type and histology. *PLoS One*. 2018;13(10):1–10.

50. Merritt MA, Pari MD, Vitonis AF, Titus LJ, Cramer DW, and Terry KL. Reproductive Characteristics In Relation to Ovarian Cancer Risk by Histologic Pathways. *Human Reproduction*. 2013;28(5):1406-1417
51. Wentzensen N, Poole EM, Trabert B, White E, Arslan AA, Patel AV, et al. Ovarian Cancer Risk Factors by Histologic Subtype: An Analysis From the Ovarian Cancer Cohort Consortium. *Journal of Clinical Oncology*. 2016;34(24):2888-289
52. Momenimovahed Z, Tiznobaik A, Taheri S, Salehiniya H. Ovarian cancer in the world: Epidemiology and risk factors. Vol. 11, *International Journal of Women's Health*. 2019. p. 287–99.
53. Adriani P. Hubungan Paritas Dan Usia Ibu Dengan Kista Ovarium Di RSUD dr. R. Goeteng Tarunadibrata Purbalingga. *Publ Kebidanan*. 2018;9(1):57–66.
54. Abeln ECA, Smit VTHBM, Wessels JW, De Leeuw WJF, Cornelisse CJ, Fleuren GJ. Molecular genetic evidence for the conversion hypothesis of the origin of malignant mixed Mullerian tumours. *J Pathol*. 1997;183(4):424–31.
55. Raspollini MR, Lopez-Beltran A, editors. *Gynecologic and Urologic Pathology: Similarities, Differences and Challenges*. Cambridge: Cambridge University Press; 2019.
56. Prat J. Staging classification for cancer of the ovary, fallopian tube, and peritoneum. *Int J Gynecol Obstet* [Internet]. 2014;124(1):1–5. Available from: <http://dx.doi.org/10.1016/j.ijgo.2013.10.001>
57. Resti Arania I W. Karakteristik Pasien Kanker Ovarium di Rumah Sakit Dr. H. Abdul Moeloek Bandar Lampung Tahun 2009-2013. 2018;25(1):212–20.
58. MULAWARDHANA, P., ASKANDAR, B., & -, S. (2012). Comparison Between HE4, CA-125, and Combination of Both HE4 and CA-125 as Tumor Markers for Epithelial Ovarian Carcinoma Patients. *Indonesian Journal of Cancer*, 6(2). doi:<http://dx.doi.org/10.33371/ijoc.v6i2.166>

59. Yokoyama Y, Moriya T, Takano T, Shoji T, Takahashi O, Nakahara K, et al. Clinical outcome and risk factors for recurrence in borderline ovarian tumours. *Br J Cancer* [Internet]. 2006;94(11):1586–91. Available from: <https://doi.org/10.1038/sj.bjc.6603139>
60. Schilder JM, Thompson AM, DePriest PD, Ueland FR, Cibull ML, Kryscio RJ, et al. Outcome of reproductive age women with stage IA or IC invasive epithelial ovarian cancer treated with fertility-sparing therapy. *Gynecol Oncol*. 2002 Oct;87(1):1–7.
61. Tortorella L, Vizzielli G, Fusco D, Cho WC, Bernabei R, Scambia G, et al. Ovarian Cancer Management in the Oldest Old: Improving Outcomes and Tailoring Treatments. *Aging Dis*. 2017 Oct;8(5):677–84.
62. O'Neill K E, Maher J Y, Laronda M M, Duncan F E, LeDuc R D, Lujan M E, Gomez-Lobo V. Anatomic nomenclature and 3-dimensional regional model of the human ovary: call for a new paradigm. *American journal of obstetrics and gynecology*; (2022).
63. Silva E G, Kim G, Bakkar R, Bozdog Z, Shaye-Brown A, Loghavi S, Pinto K. Histology of the normal ovary in premenopausal patients. *Annals of Diagnostic Pathology*; (2020). 46, 151475.
64. Musselman K, Glynn S, Mosquera J M, Elemento O, Sboner A, Beltran H, Holcomb K. Identification of a therapeutic target using molecular sequencing for treatment of recurrent uterine serous adenocarcinoma. *Gynecologic Oncology Reports*; (2019). 28, 54-57.
65. Iversen L, Sivasubramaniam S, Lee A J, Fielding S, Hannaford P C. Lifetime cancer risk and combined oral contraceptives: the Royal College of General Practitioners' Oral Contraception Study. *American journal of obstetrics and gynecology*; (2017). 216(6), 580-e1.
66. Huq M R, Woodard N, Okwara L, McCarthy S, Knott C L. Breast cancer knowledge & information seeking among African American women below screening age. *Patient Education and Counseling*. (2022).

67. Giaquinto A N, Sung H, Miller K D, Kramer J L, Newman L A, Minihan A, Siegel R L. Breast cancer statistics, 2022. *CA: A Cancer Journal for Clinicians*; (2022). 72(6), 524-541.
68. Siegel, R. L., Miller, K. D., Fuchs, H. E., & Jemal, A. Cancer statistics, 2021. *Ca Cancer J Clin*; (2021). 71(1), 7-33.
69. Suzuki M, Matsushima-Nishiwaki R, Kuroyanagi G, Suzuki N, Takamatsu R, Furui T, Morishige K I. Regulation by heat shock protein 22 (HSPB8) of transforming growth factor- $\alpha$ -induced ovary cancer cell migration. *Archives of biochemistry and biophysics*; (2015). 571, 40-49.
70. Momenimovahed Z, Tiznobaik A, Taheri S, Salehiniya H. Ovarian cancer in the world: epidemiology and risk factors. *International journal of women's health*; (2019). 11, 287.
71. Amita M, Takahashi T, Igarashi H, Nagase S. Clomiphene citrate down-regulates estrogen receptor- $\alpha$  through the ubiquitin-proteasome pathway in a human endometrial cancer cell line. *Molecular and Cellular Endocrinology*; (2016). 428, 142-147.
72. Arania R, Windarti I. Karakteristik Pasien Kanker Ovarium di Rumah Sakit Dr. H. Abdul Moeloek Bandar Lampung Tahun 2009-2013. *Juke Unila*; (2015). 5(9), 43-47.
73. Ding H, Zhang J, Zhang F, Xu Y, Yu Y, Liang W, Li Q. Role of Cancer-Associated fibroblast in the pathogenesis of ovarian Cancer: Focus on the latest therapeutic approaches. *International Immunopharmacology*; (2022). 110, 109052.